COPD Patients Face Severe Risks from Combined Smoke Exposure
A new study reveals that patients with COPD exposed to both cigarette and biomass smoke experience significantly worse health outcomes.
Patients exposed to combined smoke show poorer lung function and more severe exacerbations.
The study analyzed 319 COPD patients in Türkiye, revealing alarming statistics on dual exposure.
Combined exposure increases the risk of pulmonary hypertension and chronic respiratory failure.
A recent observational study has highlighted the detrimental effects of combined exposure to cigarette and biomass smoke on patients with Chronic Obstructive Pulmonary Disease (COPD). Conducted in Türkiye, the research involved 319 patients treated at two tertiary care centers between January 2024 and August 2025. Results indicated that individuals exposed to both smoke sources exhibited significantly worse lung function and higher rates of exacerbations compared to those exposed to either smoke type alone.
The study categorized participants into three groups: those who smoked cigarettes only (159 patients), those exposed to biomass smoke only (80 patients), and those with combined exposure (80 patients). Notably, the group with dual exposure, despite being younger, had a mean forced expiratory volume in one second (FEV1) of just 48.27% of the predicted value, which is considerably lower than the 55.28% in the cigarette-only group and 55.62% in the biomass group. This stark difference underscores the severity of respiratory impairment associated with combined smoke exposure.
Moreover, patients with dual exposure reported a higher average of 2.18 annual COPD exacerbations, compared to 2.08 for cigarette smokers and 1.88 for those exposed to biomass smoke. Severe exacerbations were also more prevalent in the combined exposure group, averaging 1.78 annually, which is significantly higher than the other two groups. The study found that those with combined exposure had an 89% increased likelihood of experiencing severe exacerbations compared to those who smoked cigarettes alone.
In addition to exacerbations, the study revealed concerning rates of pulmonary hypertension and chronic respiratory failure among patients with combined exposure. Approximately 22.5% of these patients were affected by pulmonary hypertension, compared to 10.1% of smokers and 8.75% of those exposed to biomass smoke. The need for long-term oxygen therapy was also more pronounced in the combined group, with 26.2% requiring it, compared to 17.0% and 11.2% in the other groups.
These findings emphasize the critical need for healthcare providers to assess both cigarette and biomass smoke exposure when evaluating COPD severity. While the retrospective nature of the study limits causal conclusions, it highlights the urgent need for larger prospective studies to further investigate the independent effects of dual exposure on disease progression.
